Data from the Dutch COBRA study show that RA mortality is normalised when compared to the general population after 23 years of follow-up. These findings confirm that early, intensive treatment of rheumatoid arthritis (RA) – which may include the use of glucocorticoids – offers long-term benefits and strongly suggests these benefits include reduced mortality towards controls. Mortality in patients with RA is known to be higher than what has been observed in the general population.[1-3] The adverse effects of the disease also take some time to show; they become apparent after more than a decade. Yet, it was unknown whether early, intensive treatment improved mortality rates. Research from the COmbinatietherapie Bij Rheumatoïde Artritis (COBRA) trial, a prospective cohort study of early RA, showed that early RA treatment provides long-term effectiveness without causing undue harm.
Patients with early RA (median disease duration 4 months) were treated with sulphala...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Novel Systemic Sclerosis Drugs: An Overview of What Might Be to Come Next Article
Clinical Effect of Vedolizumab on Articular Manifestations Spondyloarthritis Associated with IBD »
Table of Contents: EULAR 2018
Psoriasis and Psoriatic Arthritis
Osteoporosis and Osteoarthritis
Systemic Sclerosis and Systemic Lupus Erythematosus
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.